Kinnear Pharmaceuticals

Kinnear Pharmaceuticals is a private, preclinical-stage biotech company based in San Diego, founded in 2019. The company is developing a versatile immunomodulatory drug platform based on synthetic Ceragenins, small molecules designed to mimic and enhance the body's innate immune defenses against pathogens. Its lead candidate, CSA-131, has received FDA Qualified Infectious Disease Product (QIDP) designation for preventing/treating infections in cystic fibrosis patients. Kinnear's strategy targets difficult-to-treat infections, aiming to overcome antimicrobial resistance with a novel mechanism of action.

Ceragenins: synthetic non-peptide small molecules modeled after host defense peptides (e.g., LL-37) of the innate immune system. They have a cationic sterol-based structure that targets pathogen membranes, offering broad-spectrum antimicrobial activity against bacteria/fungi, anti-inflammatory effects, and a proposed low resistance profile.

Kinnear competes in the novel anti-infective space with companies developing next-generation antibiotics, antimicrobial peptides, phage therapies, and other immunomodulatory approaches. Key differentiators are the Ceragenins' synthetic nature (vs. peptide stability issues), dual antimicrobial/anti-inflammatory action, and targeting of membrane electrostatics to avoid traditional resistance mechanisms.